Relative Reactivity of anti- and syn-Oximino Carbonates and Carbamates of 2-Pyridylacetic Acid Esters
摘要:
[GRAPHICS]anti-Oximes of 2-pyridylacetic acid esters are rapidly transformed to pyridine-2-carbonitrile under a variety of conditions while syn-oximes bearing tert-butyl esters can be conveniently deprotected to the corresponding carboxylic acid with subsequent fragmentation to the nitrile.
A One-Pot Sonogashira Coupling and Annulation Reaction: An Efficient Route toward 4H-Quinolizin-4-ones
作者:Zhengwang Chen、Tanggao Liu、Xiaoyue Ma、Pei Liang、Lipeng Long、Min Ye
DOI:10.1055/s-0037-1611748
日期:2019.4
An efficient one-pot Sonogashira coupling and annulation reaction affording 4 H -quinolizin-4-ones in moderate to excellent yields is described. A variety of substituted iodoarenes and 2-alkylazaarenes were well tolerated, and especially the unsaturated double and triple bonds were compatible under the standard conditions.
An expedient synthesis of β-aralkyl cycloalkanones via the sequential conjugate addition of allyl arylacetates and Pd-catalyzed decarboxylative protonation protocol
作者:Se Hee Kim、Hyun Seung Lee、Sung Hwan Kim、Jae Nyoung Kim
DOI:10.1016/j.tetlet.2009.04.006
日期:2009.6
An expedient protocol for the synthesis of β-aralkyl cycloalkanones was developed via the conjugate addition of allyl arylacetate to cycloalkenones and the following Pd-catalyzed decarboxylative protonation strategy.
[EN] INHIBITORS OF HDME<br/>[FR] INHIBITEURS DE HDME
申请人:EPITHERAPEUTICS APS
公开号:WO2012007007A1
公开(公告)日:2012-01-19
The present invention relates to compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic disregulation is involved in the pathogenesis, such as e.g. cancer. The present invention also relates to pharmaceutical compositions comprising said compounds and to the use of such compounds as a medicament.
Di-aryl substituted ethane pyridones, particularly ethane pyridones substituted with i) a phenyl, ii) a pyridyl, iii) a thiazole, iv) a pyrimidinyl, v) a pyridazinyl, vi) a furyl, vii) a thienyl, viii) an oxazolyl, ix) an isoxazolyl, or x) an isothiazolyl moiety are phosphodiesterase-4 inhibitors useful in the treatment or prevention of asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial, fungal or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the brain; psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; osteoarthritis; inflammation; or cytokine-mediated chronic tissue degeneration. Formula (I) wherein X is phenyl, pyridinyl, thiazolyl, pyrimidinyl, pyridazinyl, furyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl.